Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: E.Coli Infections Clear all
Recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

NCT06938867
View directory record Official record
Conditions
E Coli Infections, Allogenic Transplant Patients
Interventions
SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli, Placebo 10 mL
Biological · Other
Lead sponsor
SNIPR Biome Aps.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Duarte, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Results available

Corticosteroids for Children With Febrile Urinary Tract Infections

NCT01391793
View directory record Official record
Conditions
Acute Urinary Tract Infection, Urinary Tract Infection
Interventions
Placebo, Dexamethasone
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
2 Months to 6 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 1 Interventional

E. Coli for Prevention of Catheter UTI in SCI Patients

NCT00458471
View directory record Official record
Conditions
Urinary Tract Infection(UTI)
Interventions
Insertion of a urinary catheter coated with benign E. coli
Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2007 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Challenge Study of an ETEC Vaccine

NCT01922856
View directory record Official record
Conditions
Enteritis; Escherichia Coli, Enterotoxigenic
Interventions
LTR192G with dscCfaE, No Intervention
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Jul 23, 2026, 6:16 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Enteroaggregative E.Coli (EAEC)

NCT00362869
View directory record Official record
Conditions
Escherichia Coli Infections
Interventions
Levofloxacin, Placebo, Enteroaggregative E. coli (EAEC)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Jul 23, 2026, 6:16 PM EDT
Not yet recruiting Phase 2 Interventional

Cefotetan Therapy for Escherichia Coli Infections

NCT07318584
View directory record Official record
Conditions
E Coli Infection, ESBL Producing E.Coli
Interventions
Cefotetan, Carbapenems, Beta Lactam Antibiotics
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 23, 2026, 6:16 PM EDT
Withdrawn No phase listed Observational

Ampicillin-sulbactam Resistant E.Coli at UPMC

NCT00619580
View directory record Official record
Conditions
Positive E Coli Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2014 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

NCT05138822
View directory record Official record
Conditions
Uncomplicated Urinary Tract Infections, Urinary Tract Infections
Interventions
GSK3882347, Nitrofurantoin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Anniston, Alabama • Lomita, California • Modesto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"

NCT01595529
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Cefixime, Cephalexin, Placebo, Trimethoprim/Sulfamethoxazole
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 10 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Results available

Colonizing Neurogenic Bladders With Benign Flora

NCT00371631
View directory record Official record
Conditions
Spinal Cord Injury, Urinary Tract Infection
Interventions
Insertion of urinary catheters coated with E. coli 83972
Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Jul 23, 2026, 6:16 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

NCT06702449
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
448 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
6
States / cities
Lenexa, Kansas • Secaucus, New Jersey • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)

NCT03404674
View directory record Official record
Conditions
Diarrhea
Interventions
CssBA, dmLT
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli

NCT04191148
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
LBP-EC01, Placebo
Drug
Lead sponsor
Locus Biosciences
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Anniston, Alabama • Irvine, California • Doral, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Jul 23, 2026, 6:16 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults

NCT03038243
View directory record Official record
Conditions
Shigella Sonnei Dysenteries
Interventions
Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT), Shigella flexneri 2a whole cell (Sf2aWC) vaccine, Placebo
Biological · Other
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Jul 23, 2026, 6:16 PM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

NCT00654108
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.

NCT00328380
View directory record Official record
Conditions
Diarrhea
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
3
States / cities
South Miami, Florida • Houston, Texas • La Porte, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122

NCT04634513
View directory record Official record
Conditions
Shigella Infection, Enterotoxigenic Escherichia Coli Infection
Interventions
strain CVD 1208S-122, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 23, 2026, 6:16 PM EDT
Completed No phase listed Observational

Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli

NCT00573235
View directory record Official record
Conditions
Enterobacteriaceae Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea

NCT01644565
View directory record Official record
Conditions
Escherichia Coli Infection
Interventions
Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5, Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Results available

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00671034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Pharmacological Study, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 30 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant

NCT03922061
View directory record Official record
Conditions
Polio
Interventions
dmLT, fIPV
Biological
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Not applicable Interventional

Prevention of Urinary Tract Infection (UTI) in Persons With Spinal Cord Injury (SCI)

NCT00309114
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
bacterial interference
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
15 Years to 64 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jul 23, 2026, 6:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cranberry for UTI Prevention in Residents of Long Term Care Facilities

NCT00596635
View directory record Official record
Conditions
Urinary Tract Infection
Interventions
Once Daily Cranberry Capsule, Twice Daily Cranberry Capsules
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
60 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Jul 23, 2026, 6:16 PM EDT